Fig. 2From: Systemic bevacizumab for high-output cardiac failure in hereditary hemorrhagic telangiectasia: an international survey of HHT centersRates of bevacizumab adverse effects (such as hypertension, proteinuria, or poor wound healing) and discontinuation reported by HHT centers. Bar color represents response selected by respondent (e.g. 10â19% of patients treated at their center had an adverse event) and bar height reports the number of centers responding with that category for a given question. One center that reported treating 2 patients reported that both had treatment discontinued for lack of response (not shown in figure)Back to article page